主要教育和工作經(jīng)歷：　 1986年中山醫(yī)科大學(xué)畢業(yè)，先后獲碩士、博士學(xué)位。從事臨床腫瘤診療工作三十余年，曾任中山大學(xué)附屬第一醫(yī)院腫瘤科主任多年。 社會兼職：現(xiàn)任中國腫瘤臨床學(xué)會（CSCO）理事、CSCO罕見腫瘤專委會常委、中華醫(yī)學(xué)會腫瘤分會腫瘤內(nèi)科專委會委員、中國南方腫瘤臨床研究協(xié)會（CSWOG）常委；廣東省抗癌協(xié)會化療專委會副主委；廣東省健康管理學(xué)會副秘書長及腫瘤防治專委會副主委；廣州抗癌協(xié)會胃癌專委會主委等。 主要論著（SCI，第一作者/通信作者）： 1、Ying He*, Zhousan Zheng*, Yi Xu*, Huiwen Weng, Ying Gao, Kai Qin, Jian Rong, Cui Chen, Miao Yun, Jiaxing Zhang, Sheng Ye(葉升，通訊作者).Over-expression of IMPDH2 is associated with tumor progression and poor prognosis in hepatocellular carcinoma.Am J Cancer Res 2018;8(8):1604-1614.（IF=4.737） 2、Yi Xu#, Zhousan Zheng#, Ying Gao#, Shiyu Duan, Cui Chen, Jian Rong, Kebing Wang,MiaoYun, Huiwen Weng, ShengYe*(葉升，共同通訊作者) & Jiaxing Zhang*. High expression of IMPDH2 is associated with aggressive features and poor prognosis of primary nasopharyngeal carcinoma. Scientific Reports. 2017 Apr 7;7(1):745.（IF=4.122） 3、Ying Gao#, Mengping Zhang #, Zhousan Zheng#, Ying He #, Yujia Zhu, Quanyong Cheng, Jian Rong, Huiwen Weng, Cui Chen, Yi Xu, Miao Yun, Jiaxing Zhang* and Sheng Ye*(葉升，通訊作者). Over-expression of protein tyrosine phosphatase 4A2 correlates with tumor progression and poor prognosis in nasopharyngeal carcinoma. Oncotarget. 2017 Aug 24;8(44):77527-77539.（IF=5.168） 4、Zhang JX, Chen ZH, Xu Y, Chen JW, Weng HW, Yun M, Zheng ZS, Chen C, Wu BL, Li EM, Fu JH,Ye S(葉升，通訊作者), and Xie D. Downregulation of MicroRNA-644a Promotes Esophageal Squamous Cell Carcinoma Aggressiveness and Stem-cell-like Phenotype via Dysregulation of PITX2. Clinical Cancer Research（IF=8.738）.2016 Jul 12. pii:clincanres.0414.2016. doi: 10.1158/1078-0432.CCR-16-0414.PMID: 27407092. 5、Xu Y, Rong J, Duan SY, Chen C, Li Y, Peng BG, Yi B,Zheng ZS, Gao Y, Wang KB, Yun M, Weng HW, Zhang JX, Ye S(葉升，通訊作者).High expression of GNA13 is associated with poor prognosis in hepatocellular carcinoma.Scientific Reports（IF=5.228）. 6、Zhang JX, Yun M, Xu Y, Chen JW, Weng HW, Zheng ZS, Chen C, Xie D, YeS（葉升，通訊作者）.GNA13 as a prognostic factor and mediator of gastric cancerprogression.Oncotarget（IF=6.359）.2015...

從事腫瘤內(nèi)科領(lǐng)域三十余年，是資深臨床腫瘤專家。擅長罕見腫瘤、肺癌、胃癌、結(jié)直腸癌、肝癌、膀胱癌、腎癌等惡性腫瘤的診斷及綜合治療，尤其是惡性腫瘤的免疫治療、分子靶向治療及化療。